Last reviewed · How we verify
Hyperimmune plasma
At a glance
| Generic name | Hyperimmune plasma |
|---|---|
| Sponsor | Andalusian Network for Design and Translation of Advanced Therapies |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
- Convalescent Plasma in Hospitalized COVID-19 Patients
- A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) (PHASE3)
- Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients (PHASE2, PHASE3)
- Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection (PHASE1, PHASE2)
- Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) (PHASE3)
- Early Use of Hyperimmune Plasma in COVID-19 (NA)
- Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: